Sanofi hints at 'class effect' for mRNA flu shot as it unveils vaccine R&D plans driven by $3.2B deal

29 Jun 2023

VaccinemRNAPhase 3

French drugmaker Sanofi showcased its vaccine franchise, part of a promise made two years ago to overhaul what the company at the time acknowledged was a lagging part of its business.

Ahead of an event in London on Thursday, the company previewed new data from a dozen vaccine products in development, including two mRNA-based flu shots, RSV products, a pneumococcal vaccine, vaccines for meningitis B and chlamydia, and a therapeutic acne vaccine. Two of those — an RSV vaccine and a pneumococcal vaccine — are slated to enter Phase III in the first half of 2024.

Sanofi hints at 'class effect' for mRNA flu shot as it unveils vaccine R&D plans driven by $3.2B deal

Preview

Source: EndPoints

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Sanofi

Indications

Influenza, HumanMeningitis, MeningococcalChlamydia Infections

Targets

Drugs

RSV vaccine (South China Vaccine)Pneumococcal vaccine(GSK)

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.